Table 2. Effect of anagrelide treatment... | American Society of Hematology

Table 2.

Effect of anagrelide treatment on MK mass in essential thrombocythemia

	Platelet count (× 10⁹/L)	MK/NEP^*(× 10⁻³)	MK number (× 10⁶/kg)^†	MK volume (× 10³μm³)	MK mass (× 10¹⁰μm³/kg)
Controls (n = 14)	240 ± 60^‡	1.3 ± 0.8	7.1 ± 2.4	25.9 ± 4.7	18.4 ± 7.2
Patients (n = 10)
Before treatment	1062 ± 419	2.6 ± 1.5	13.9 ± 2.6	47.7 ± 8.5	66.3 ± 13.2
After treatment	361 ± 53	1.6 ± 0.8	8.3 ± 2.5	33.8 ± 5.2	27.8 ± 8.3
Ratio
Before treatment/HC	4.4	1.5	2	1.8	3.6
After treatment/HC	1.5	1.2	1.2	1.3	1.5
Before/after treatment	2.9	1.6	1.7	1.4	2.4

	Platelet count (× 10⁹/L)	MK/NEP^*(× 10⁻³)	MK number (× 10⁶/kg)^†	MK volume (× 10³μm³)	MK mass (× 10¹⁰μm³/kg)
Controls (n = 14)	240 ± 60^‡	1.3 ± 0.8	7.1 ± 2.4	25.9 ± 4.7	18.4 ± 7.2
Patients (n = 10)
Before treatment	1062 ± 419	2.6 ± 1.5	13.9 ± 2.6	47.7 ± 8.5	66.3 ± 13.2
After treatment	361 ± 53	1.6 ± 0.8	8.3 ± 2.5	33.8 ± 5.2	27.8 ± 8.3
Ratio
Before treatment/HC	4.4	1.5	2	1.8	3.6
After treatment/HC	1.5	1.2	1.2	1.3	1.5
Before/after treatment	2.9	1.6	1.7	1.4	2.4

Nucleated marrow erythroid precursor cells (MK/NEPs ratio of 1.3 = 1.3 × 10⁻³).

Derived from normal erythroid number (5.3 × 10⁹ cells/kg, see “Patients, materials, and methods”).

Mean ± 1 SD.

HC indicates healthy controls.